DTIL - Precision BioSciences - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-70.53M

Cash

137.8M

Avg Qtr Burn

-11.31M

Short % of Float

1.92%

Insider Ownership

14.90%

Institutional Own.

43.77%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Azer-cel (PBCAR0191) (azercabtagene zapreleucel) Details Cancer, B-cell lymphoma, Diffuse large B cell lymphoma	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PBCAR19B (CD19 Allogeneic CAR-T) Details Non-Hodgkin lymphoma, Cancer, Diffuse large B cell lymphoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PBCAR20A (targeting CD20) Details Non-Hodgkin lymphoma, Cancer, Chronic lymphocytic leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PBCAR269A (BCMA) Details Cancer, Multiple myeloma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.